182 related articles for article (PubMed ID: 35581529)
1. Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate.
Liang LY; Yip TC; Lai JC; Lam AS; Tse YK; Hui VW; Chan HL; Wong VW; Wong GL
J Med Virol; 2022 Sep; 94(9):4440-4448. PubMed ID: 35581529
[TBL] [Abstract][Full Text] [Related]
2. Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study.
Kovari H; Surial B; Tarr PE; Cavassini M; Calmy A; Schmid P; Bernasconi E; Rauch A; Wandeler G; Ledergerber B;
HIV Med; 2021 Aug; 22(7):623-628. PubMed ID: 33880839
[TBL] [Abstract][Full Text] [Related]
3. Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
Toyoda H; Leong J; Landis C; Atsukawa M; Watanabe T; Huang DQ; Liu J; Quek SXZ; Ishikawa T; Arai T; Yokohama K; Chuma M; Takaguchi K; Uojima H; Senoo T; Dang H; Maeda M; Hoang J; Le RH; Yasuda S; Thin KN; Tran S; Chien N; Henry L; Asai A; Fukunishi S; Cheung R; Lim SG; Trinh HN; Nguyen MH
Hepatology; 2021 Aug; 74(2):656-666. PubMed ID: 33706421
[TBL] [Abstract][Full Text] [Related]
4. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.
Agarwal K; Brunetto M; Seto WK; Lim YS; Fung S; Marcellin P; Ahn SH; Izumi N; Chuang WL; Bae H; Sharma M; Janssen HLA; Pan CQ; Çelen MK; Furusyo N; Shalimar D; Yoon KT; Trinh H; Flaherty JF; Gaggar A; Lau AH; Cathcart AL; Lin L; Bhardwaj N; Suri V; Mani Subramanian G; Gane EJ; Buti M; Chan HLY; ;
J Hepatol; 2018 Apr; 68(4):672-681. PubMed ID: 29756595
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: Effect of Antiretroviral Switch From Tenofovir Disoproxil fumarate to Tenofovir Alafenamide on Alanine Aminotransferase, Lipid Profiles, and Renal Function in HIV/HBV-Coinfected Individuals in a Nationwide Canadian Study.
Sarowar A; Coffin CS; Fung S; Wong A; Doucette K; Truong D; Conway B; Haylock-Jacobs S; Ramji A; Hansen BE; Janssen HLA; Cooper C
J Acquir Immune Defic Syndr; 2022 Dec; 91(4):368-372. PubMed ID: 36288543
[TBL] [Abstract][Full Text] [Related]
6. Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study.
Su PY; Su WW; Hsu YC; Huang SP; Yen HH
PeerJ; 2021; 9():e12527. PubMed ID: 34820208
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate.
Kaneko S; Kurosaki M; Tamaki N; Itakura J; Hayashi T; Kirino S; Osawa L; Watakabe K; Okada M; Wang W; Shimizu T; Higuchi M; Takaura K; Yasui Y; Tsuchiya K; Nakanishi H; Takahashi Y; Watanabe M; Izumi N
J Gastroenterol Hepatol; 2019 Nov; 34(11):2004-2010. PubMed ID: 31017689
[TBL] [Abstract][Full Text] [Related]
8. First-line therapies for hepatitis B in the United States: A 3-year prospective and multicenter real-world study after approval of tenofovir alefenamide.
Pan CQ; Afdhal NH; Ankoma-Sey V; Bae H; Curry MP; Dieterich D; Frazier L; Frick A; Hann HW; Kim WR; Kwo P; Milligan S; Tong MJ; Reddy KR
Hepatol Commun; 2022 Aug; 6(8):1881-1894. PubMed ID: 35445803
[TBL] [Abstract][Full Text] [Related]
9. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B.
Nam H; Han JW; Lee SK; Yang H; Lee HL; Sung PS; Song MJ; Kwon JH; Jang JW; Chang UI; Kim CW; Nam SW; Bae SH; Choi JY; Yoon SK; Yang JM; Kim HY
J Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38690711
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.
Byun KS; Choi J; Kim JH; Lee YS; Lee HC; Kim YJ; Yoo BC; Kwon SY; Gwak GY; Lim YS
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):427-437.e5. PubMed ID: 33962041
[TBL] [Abstract][Full Text] [Related]
11. Improved bone and renal safety in younger tenofovir disoproxil fumarate experienced chronic hepatitis B patients after switching to tenofovir alafenamide or entecavir.
Da Wang F; Zhou J; Li LQ; Li YJ; Wang ML; Tao YC; Zhang DM; Wang YH; Chen EQ
Ann Hepatol; 2023; 28(5):101119. PubMed ID: 37271480
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study.
Farag MS; Fung S; Tam E; Doucette K; Wong A; Ramji A; Conway B; Cooper C; Tsoi K; Wong P; Sebastiani G; Brahmania M; Haylock-Jacobs S; Coffin CS; Hansen BE; Janssen HLA
J Viral Hepat; 2021 Jun; 28(6):942-950. PubMed ID: 33749086
[TBL] [Abstract][Full Text] [Related]
13. Renal and bone side effects of long-term use of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide fumarate in patients with Hepatitis B: a network meta-analysis.
Liu Z; Zhao Z; Ma X; Liu S; Xin Y
BMC Gastroenterol; 2023 Nov; 23(1):384. PubMed ID: 37950196
[TBL] [Abstract][Full Text] [Related]
14. Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
Fong TL; Lee BT; Tien A; Chang M; Lim C; Ahn A; Bae HS
J Viral Hepat; 2019 May; 26(5):561-567. PubMed ID: 30576085
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effectiveness analysis of tenofovir alafenamide and tenofovir disoproxil fumarate on the treatment for chronic hepatitis B.
Liu R; Qiao J; Zhang L; Dou Z
Medicine (Baltimore); 2024 May; 103(20):e37953. PubMed ID: 38758884
[TBL] [Abstract][Full Text] [Related]
16. Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction-A Prospective Cohort Study.
Surial B; Béguelin C; Chave JP; Stöckle M; Boillat-Blanco N; Doco-Lecompte T; Bernasconi E; Fehr J; Günthard HF; Schmid P; Walti LN; Furrer H; Rauch A; Wandeler G;
J Acquir Immune Defic Syndr; 2020 Oct; 85(2):227-232. PubMed ID: 32925387
[TBL] [Abstract][Full Text] [Related]
17. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile.
Squillace N; Ricci E; Menzaghi B; De Socio GV; Passerini S; Martinelli C; Mameli MS; Maggi P; Falasca K; Cordier L; Celesia BM; Salomoni E; Di Biagio A; Pellicanò GF; Bonfanti P;
Drug Des Devel Ther; 2020; 14():5515-5520. PubMed ID: 33364747
[TBL] [Abstract][Full Text] [Related]
19. Five-year Treatment with Tenofovir Alafenamide Achieves High Rates of Viral Suppression, Alanine Aminotransferase Normalization, and Favorable Bone and Renal Safety in Chinese Chronic Hepatitis B Patients.
Hou J; Ning Q; Duan Z; Chen Y; Xie Q; Zhang L; Wu S; Tang H; Li J; Lin F; Yang Y; Gong G; Luo Y; Xie S; Wang H; Mateo R; Yazdi T; Abramov F; Yee LJ; Flaherty J; Chen C; Huang Y; Zhang M; Jia J
J Clin Transl Hepatol; 2024 May; 12(5):469-480. PubMed ID: 38779514
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B.
Lim J; Choi WM; Shim JH; Lee D; Kim KM; Lim YS; Lee HC; Choi J
Liver Int; 2022 Jul; 42(7):1517-1527. PubMed ID: 35343041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
